This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lenz, H.-J. Search for Related Content PubMed PubMed Citation Articles by Lenz, H.-J.

Symptom Management and Supportive Care

Management and Preparedness for Infusion and Hypersensitivity Reactions

University of Southern California, Los Angeles, California, USA

Key Words. Hypersensitivity • Infusion reactions • Monoclonal antibodies • Taxanes • Platinum • Rechallenge

Correspondence: Heinz-Josef Lenz, M.D., F.A.C.P., USC/Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Room 3456, Los Angeles, California 90033, USA. Telephone: 323-865-3955; Fax: 323-865-0061; e-mail: lenz{at}usc.edu (cc to assistant: ramirez4{at}usc.edu)

Background. Like nearly all systemic cancer therapies, monoclonal antibodies are associated with hypersensitivity reactions. This article reviews the characteristics and management of hypersensitivity reactions to monoclonal antibodies and commonly used chemotherapy agents.

Methods. MEDLINE was searched for recent studies and reviews pertaining to hypersensitivity reactions with monoclonal antibodies (cetuximab, rituximab, trastuzumab, panitumumab, bevacizumab), platinum compounds (carboplatin, oxaliplatin), and taxanes (paclitaxel, docetaxel). Emphasis was placed on articles that provided practical information on hypersensitivity reaction management. Data found in the literature were supplemented with information from the package insert for each agent.

Results. Severe hypersensitivity reactions are rare, with an incidence of 5%, provided patients receive proper premedication, close monitoring, and prompt intervention when symptoms occur. Hypersensitivity reactions to platinum compounds are generally consistent with type 1 hypersensitivity, occurring after multiple cycles of therapy. Reactions to taxanes and monoclonal antibodies produce similar symptoms, but are generally immediate, occurring during the first few minutes of the first or second infusion. However, 10%–30% of reactions to monoclonal antibodies are delayed, and may occur in later infusions, indicating the importance of close observation of the patient following administration. Mild-to-moderate reactions can be managed by temporary infusion interruption, reduction of the infusion rate, and symptom management. Rechallenge should be considered after complete resolution of all symptoms. Severe reactions may require treatment discontinuation.

Conclusion. Hypersensitivity or infusion reactions to platinum compounds are acquired; reactions to taxanes and monoclonal antibodies are immediate and typically occur during the first few minutes of the first infusion. The different time of onset should be considered when developing strategies for preventing and managing hypersensitivity reactions. The decision to rechallenge or discontinue treatment after a reaction occurs depends on the severity of the reaction and other clinical factors.

Disclosure of potential conflicts of interest is found at the end of this article.

This article has been cited by other articles:

				P. K Coyle, J. F Foley, E. J Fox, D. R Jeffery, F. E Munschauer III, and C. Tornatore Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy Multiple Sclerosis, November 1, 2009; 15(4_suppl): S26 - S36. [Abstract] [PDF]

				Y. Ichikawa, A. Goto, S. Hirokawa, M. Kijima, T. Ishikawa, T. Chishima, H. Suwa, H. Yamamoto, S. Yamagishi, S. Osada, et al. Allergic Reactions to Oxaliplatin in a Single Institute in Japan Jpn. J. Clin. Oncol., September 1, 2009; 39(9): 616 - 620. [Abstract] [Full Text] [PDF]

				S. S. Shord, L. R. Bressler, L. A. Tierney, S. Cuellar, and A. George Understanding and managing the possible adverse effects associated with bevacizumab Am. J. Health Syst. Pharm., June 1, 2009; 66(11): 999 - 1013. [Abstract] [Full Text] [PDF]

				L. Boehnke Michaud The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer Journal of Oncology Pharmacy Practice, June 1, 2009; 15(2): 95 - 106. [Abstract] [PDF]

				L. Fong and E. J. Small Anti-Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment J. Clin. Oncol., November 10, 2008; 26(32): 5275 - 5283. [Abstract] [Full Text] [PDF]

				S. Goodin Ixabepilone: A novel microtubule-stabilizing agent for the treatment of metastatic breast cancer Am. J. Health Syst. Pharm., November 1, 2008; 65(21): 2017 - 2026. [Abstract] [Full Text] [PDF]

				C. H. Chung Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy Oncologist, June 1, 2008; 13(6): 725 - 732. [Abstract] [Full Text] [PDF]